An investigational port delivery system with ranibizumab showed positive phase 2 results in patients with wet age-related macular degeneration, according to a Genentech press release.
The multicenter, randomized, interventional, active treatment-controlled LADDER study evaluated the efficacy and safety of the port delivery system (PDS), a small, refillable eye implant that continuously delivers ranibizumab over time, in 243 patients.
Those who had the PDS implanted received one of three ranibizumab concentrations, 10 mg/mL, 40 mg/mL or 100 mg/mL, the release said. Approximately 80% of
Uncategorized